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XIntroduction: In lung transplantation (LTx), the arterial partial pressure of oxygen (PaO2) is traditionally re-
garded as critical information for assessment of donor lung function. Each center sets its own thresholds; by con-
vention, a donor PaO2 of less than 300 mm Hg has been considered disqualifying. Limited literature exists to
support such a practice. We analyzed all LTxs performed in the United States over a 9-year period to assess
the effect of donor PaO2 on graft survival.
Methods: The United Network for Organ Sharing (UNOS) database was queried for LTx (January 2000–
November 2009). Of 12,545 LTx performed, 12,045 (96%) had donor PaO2 data on a fraction of inspired oxygen
of 1.0, recorded at the time of procurement.
Results:Mean donor PaO2 was 407 140 mmHg. The majority of LTxs had a donor PaO2 greater than 300 mm
Hg (9593 (80%]) whereas PaO2 was 200 mmHg or less in 1830 (15%) and 201 to 300 in 582 (5%) donors. Use
of donors with a PaO2 of less than 200 increased over time from 5% (45) in 2000 to 21% (295) in 2009
(P ¼ .002). Kaplan-Meier survival analysis showed no difference in graft survival with differing donor
PaO2s, irrespective of whether patients had a single or double LTx. A Cox multivariable analysis of 21 donor
characteristics demonstrated that donor PaO2 had no association with graft survival.
Conclusions: Donor PaO2 levels did not affect graft survival. The use of donors with lower PaO2s could sub-
stantially increase the donor pool. We are not suggesting that donor PaO2 is not important when assessing
potential lung donors but its level of importance in regard to other criteria appears less than previously believed.
(J Thorac Cardiovasc Surg 2012;143:919-25)Lung transplantation (LTx), like all solid organ transplanta-
tion, is struggling with the demand of donor organs exceed-
ing supply and increasing waitlist mortality. Therefore,
attempts to improve the supply of donor lungs by aggressive
donor management,1-3 use of ex vivo perfusion, use of
cardiac death donors, and liberalization of the donor
selection criteria4,5 are actively being practiced to
minimize the widely documented mismatch of demand
and supply.6
In current practice, arterial partial pressure of oxygen
(PaO2) is considered critical information for assessment
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The Journal of Thoracic and Caliterature recommend that the donor PaO2 should be more
than 300 mm Hg and that use of donor lungs with PaO2s
of less than 300 mm Hg could be associated with decreased
posttransplant pulmonary function. However, no significant
evidence is available to support such a practice.7,8 As stated
in the consensus report from The Pulmonary Council of the
International Society of Heart and Lung Transplantation:
The origin of the ‘‘standard’’ arterial blood gas crite-
ria for evaluating the suitability of the potential pul-
monary donor is shrouded in the mists of time. In
1987 Harjula et al9 described a single case of peri-
operative graft failure in which the arterial partial
pressure of oxygen (PaO2) was<100 mm Hg, with
a fraction of inspired oxygen (FiO2) of 0.4 (ie,
PaO2/FiO2 ratio<250), and it is likely the acceptabil-
ity ratio of 300 (PaO2 of 120 mm Hg on an FiO2 of
0.4) was then arbitrarily chosen to provide a slight
margin of safety. It is more puzzling as to why this
standard has been so closely adhered to since that re-
port. The literature provides no answers as no studies
have addressed this issue specifically.**Reprinted with permission.8
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Abbreviations and Acronyms
DCD ¼ donation after cardiac death
FiO2 ¼ fraction of inspired oxygen
ISHLT ¼ International Society for Heart and
Lung Transplantation
LTx ¼ lung transplant (transplantation)
OPTN ¼ Organ Procurement and Transplant
Network
PaO2 ¼ arterial partial pressure of oxygen
UNOS ¼ United Network for Organ Sharing
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X With no strong literature available to validate this com-
mon practice, the purpose of this study was to assess specif-
ically the effect of donor PaO2 on graft survival using
a large all-inclusive national database.METHODS
In November 2009, a retrospective analysis of Organ Procurement and
Transplant Network (OPTN) data was performed. The OPTN is the unified
transplant network established by the United States Congress under the Na-
tional Organ Transplant Act of 1984. The United Network for Organ Shar-
ing (UNOS) is a private, nonprofit organization that administers the OPTN
under federal contract.
UNOS/OPTN Thoracic database was queried for LTx from January of
2000 through November of 2009. Of the 12,545 LTx operations performed,
12,045 (96%) had donor PaO2 data on a fraction of inspired oxygen (FiO2)
of 1.0 recorded at the time of procurement. The italicized phrase is how this
data point is exactly listed in the UNOS database.
Transplants were divided into groups A to D based on donor PaO2 at the
time of procurement (A,<200; B, 201-300; C, 301-400; and D,>400 mm
Hg).
For baseline characteristics, continuous variables were compared using
the t test and analysis of variance, with the Tukeymethod for controlling for
multiple comparisons. Categorical variables were compared using the c2
test. Survival curves were estimated using the Kaplan-Meier method, and
equality of survival curves was tested using a log–rank test. Multivariate
analyses were performed using Cox proportional hazards regression simul-
taneous models, in which all 21 donor variables available in the UNOS da-
tabase were used to test their association with graft survival.
RESULTS
A total of 12,045 LTXs were analyzed, of which 40.4%
(4864) were performed in female patients. Mean donor age
was 32  15 years (median, 29 years; range, 0-75 years).
Mean recipient age was 50.7  14.7 years (median, 56
years; range,<1-81 years). Mean donor PaO2 was 408 
140 mm Hg. The majority of the transplants had a donor
PaO2 greater than 400 (7756 [64.4%]) whereas donor
PaO2 was 200 or less in 1830 (15.2%), 201 to 300 in 582
(4.8%), and 301 to 400 in 1877 (15.6%). Use of donors
with PaO2 less than 200 increased over time from 5%
(45/867) in 2000 to 21% (295/1388) in 2009 (P ¼ .002).
Donor and recipient characteristics in the different donor
PaO2 subgroups are listed in Tables 1 and 2. There was no
significant difference in length of hospital stay after920 The Journal of Thoracic and Cardiovascular Surgtransplantation (PaO2  200 mm Hg, 24  27 days; 201-
300 mm Hg, 25  33 days; 301-400 mm Hg, 24  29
days,>400 mm Hg, 24  30 days). Kaplan-Meier survival
analysis showed no significant differences in graft survival
for different donor PaO2 levels (Figure 1, A). When single
(n¼ 5019) and double (n¼ 7026) LTx recipients were eval-
uated separately, there remained no significant difference in
graft survival for different donor PaO2 levels (Figure 1, B).
A Cox proportional multivariate analysis of 21 donor char-
acteristics demonstrated that there was no association of do-
nor PaO2 as a continuous variable to graft survival (Table 3).
However, steroid dependence and hypertension appeared to
be risk factors associated with poor graft survival.
DISCUSSION
LTx is an acceptable therapy for patients with end-stage
lung disease. However, LTx is limited by an inadequate
number of donors, as is common to all other fields of solid
organ transplantation. This mismatch results in increasing
waitlist time and mortality for LTx with an average waitlist
time of 539 days and more than 7000 deaths occurring each
year in patients awaiting a lung donor.10 Two novel ap-
proaches have recently been developed to address this issue
and potentially increase the donor pool for LTx. The first ap-
proach is donation after cardiac death (DCD). The number
of programs using DCD for LTx has increased substantially;
the number of DCD lung donors has increased 24% from
2006 to 2008.11 Moreover, many studies have demonstrated
comparable if not better outcomes using DCD compared
with donation after brain death.12-14 A second novel
approach is a newly developed protective normothermic
ex vivo lung perfusion technique used to render
suboptimal lungs from a DCD or brain death donor viable
for transplantation. This system allows the lungs after
procurement to be perfused with an acellular solution for
approximately 4 hours so that the lungs can be optimized
as well as continually reassessed. Thus injured donor
lungs that were initially unsuitable for transplantation
may be successfully transplanted.15 The first prospective
clinical ex vivo perfusion trial, the ‘‘Help’’ trial, was re-
cently completed by the Toronto group. They demonstrated
that 23 LTx recipients whose donor lungs underwent ex vivo
perfusion had similar early outcomes when compared with
conventionally selected and transplanted donor lungs.16
In the attempt to increase the donor lung pool, other cen-
ters have liberalized their donor criteria, (eg, donor age>55
years, smoking>20 pack-years, pathology on chest x-ray
films, and purulent secretions at bronchoscopy) and have
demonstrated that their outcomes did not change.4,5 In
2003, the International Society for Heart and Lung
Transplantation (ISHLT) consensus group on LTx
reported the current accepted ‘‘ideal’’ donor criteria as
outlined in Table 4.8 Most of the criteria have been analyzed
and questioned for significance.17 However, 1 criterion thatery c April 2012
TABLE 1. Donor characteristics
Donor PaO2 (mm Hg) <200 (n ¼ 1830) 201-300 (n ¼ 582) 301-400 (n ¼ 1877) >400 (n ¼ 7756) Total (n ¼ 12,045)
Mean age (y) 33 ± 15 31 ± 14 34 ± 15 32 ± 14 32.3 ± 14.5
Mean weight (kg) 74 ± 17 74 ± 19 77 ± 19 72 ± 17 73 ± 17.7
#1 COD: Head trauma 50% (914) 55% (322) 50% (944) 53% (4117) 52% (6297)
#2 COD: CVA 37% (670) 32% (186) 37% (696) 36% (2763) 36% (4315)
History of smoking (>20
pack-years within recent 6 mo)
13% (246) 16% (94) 16% (302) 15% (1176) 15% (1818)
Steroid use 80% (1461) 80% (468) 76% (1418) 78% (6081) 78% (9428)
Pulmonary infection 34% (628) 29% (167) 24% (441) 25% (1897) 26% (3133)
DCD 0.9% (17) 0.9% (5) 0.7% (14) 0.6% (48) 0.7% (84)
Boldface font suggests characteristics with significant statistical differences between the groups by univariate analysis. PaO2, Arterial partial pressure of oxygen; COD, cause of
death; CVA, cerebrovascular accident; DCD, donation after cardiac death.
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Xhas always been thought to be highly associated with post-
transplant lung function and graft survival has been donor
PaO2. There are a few single-center studies demonstrating
no adverse effect on graft survival when lungs are used
from a donor with a PaO2 less than 300 mm Hg.
5,17-19
These series and the ISHLT LTx consensus group
discussion on the establishment of donor PaO2 as
a criterion spurred us to investigate the effect of donor
PaO2 on graft survival in a large multi-institutional compre-
hensive national database.
The current series demonstrated that about 20% of the
donors used for LTx in the United States over the past de-
cade had a donor PaO2 of less than 300 mm Hg at the
time of procurement. This use of donors that did not adhere
to the ‘‘ideal’’ PaO2 criterion did not affect early or midterm
graft survival. However, if low donor PaO2 were almost ex-
clusively in patients donating to single LTx recipients, then
our findings would not be surprising inasmuch as low donor
PaO2 could be secondary to single lung disease. The suc-
cessful use of a single donor lung from donors with low
PaO2 and significant contralateral lung disease is widely
documented.20 However, in the current series the use of do-
nor lungs with a PaO2 of less than 300 mm Hg was evenly
distributed among single and double LTx recipients. Also,TABLE 2. Recipient characteristics
Donor PaO2 (mm Hg) <200 (n ¼ 1830) 201-300 (n ¼ 582)
Mean age (y) 51 ± 14.6 51 ± 14.8
Age<18 y 3.8% (70) 3.6% (21)
Weight (kg) 70 ± 18.3 70 ± 18.8
#1 Diagnosis: COPD 30% (554) 34% (200)
#2 Diagnosis: IPF 29% (524) 27% (157)
Era
2000-2004 18% (332) 30% (173)
2005-2009 82% (1498) 70% (409)
Double lung 61% (1118) 62% (359)
Re-transplants 4% (77) 4% (23)
Ventilator dependant 6% (105) 6% (33)
ECMO 1% (15) 1% (8)
Boldface font suggests characteristics with significant statistical differences between the gr
obstructive pulmonary disease; IPF, interstitial pulmonary fibrosis; ECMO, extracorporea
The Journal of Thoracic and Cadespite 21% of double LTxs having a donor PaO2 of less
than 300 mmHg, PaO2 levels had no effect on graft survival
in double LTx. In fact, the recipient characteristics listed in
Table 2 demonstrate that patients receiving lungs from a do-
nor with a PaO2 of less than 300 mm Hg were more likely
(P< .05) to be undergoing a double LTx than a single
LTx. Also, the use of donor lungs with a PaO2 of less
than 300 mm Hg is becoming a more frequent practice
over time in that this practice is seen significantly more in
the 2005 to 2009 era than in the 2000 to 2004 era. One
should also note that recipients of donor lungs with
a PaO2 of less than 300 mm Hg were more likely to be me-
chanically ventilated and have interstitial pulmonary fibro-
sis, which may speak to why centers were willing to accept
less than ideal donor lungs. However, the recipients of these
lungs were not more likely to be receiving extracorporeal
membrane oxygenation or be undergoing retransplantation.
The recipients’ weight and agewere found to be statistically
different among the donor PaO2 cohorts, but it would be dif-
ficult to see the clinical relevance of recipients being 1 kg
heavier or 1 year older. An analysis of donor characteristics
(Table 1) revealed statistical differences in weight and age,
but again the clinical relevance of these very small differ-
ences is hard to determine. The pattern of differences in301-400 (n ¼ 1877) >400 (n ¼ 7756) Overall
52 ± 14.1 50 ± 14.8 51 ± 14.7
2.8% (52) 3.9% (301) 3.7% (444)
70.3 ± 18 69 ± 18.4 69 ± 18.3
36% (667) 33% (2581) 33% (4002)
26% (484) 25% (1896) 25% (3061)
42% (784) 48% (3702) 41% (4991)
58% (1093) 52% (4054) 59% (7054)
55% (1036) 58% (4513) 58% (7026)
4% (74) 4% (289) 4% (463)
5% (85) 4% (309) 4.4% (532)
1% (11) 1% (63) 0.8% (97)
oups by univariate analysis. PaO2,Arterial partial pressure of oxygen; COPD, chronic
l membrane oxygenation.
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FIGURE 1. Kaplan-Meier survival curve for overall lung transplantation
(A) and double lung transplantation (B). LTx, Lung transplantation.
TABLE 3. Multivariate analysis of 21 donor characteristics
association with graft survival
Significance
Hazard
ratio
95.0% CI
for Exp(B)
Lower Upper
ABO blood type .060 1.003 1.000 1.006
Donor age .589 .954 .803 1.133
Pulmonary infection .818 1.021 .854 1.222
Donor cause of death .487 .847 .531 1.353
Smoking history .260 1.465 .753 2.848
History of cocaine abuse .540 .900 .644 1.259
IV drug abuse .373 1.515 .608 3.777
Donor ethnicity .083 .275 .064 1.186
History of extracranial cancer .763 1.200 .366 3.930
Alcohol abuse .382 1.349 .690 2.636
History of cancer .436 .530 .107 2.617
Hypertension .018 1.792 1.105 2.904
Insulin-dependent diabetes .559 1.363 .483 3.847
History of myocardial
infarction
.974 .989 .515 1.901
History of intracranial cancer .133 .629 .344 1.151
Non–heart beating donor .797 3.117 .000 0.115
Steroid use .043 1.765 1.018 3.060
Creatinine>2 .994 1.001 .865 1.158
LVEF<30% .892 .990 .863 1.137
Donor PaO2 .526 .971 .888 1.062
Donor weight .024 .998 .996 1.000
Boldface font suggests characteristics with significant statistical differences between
the groups by univariate analysis. CI, Confidence interval; IV, intravenous; LVEF, left
ventricular ejection fraction; PaO2, arterial partial pressure of oxygen.
TABLE 4. Donor acceptability criteria
Currently accepted ‘‘ideal’’ donor
Age<55 y
ABO compatibility
Clear chest radiograph
PaO2>300 on FiO2 ¼ 1.0, PEEP 5 cm H2O
Tobacco history<20 pack-years
Absence of chest trauma
No evidence of aspiration/sepsis
No prior cardiopulmonary surgery
Sputum Gram stain—absence of organisms
Absence of purulent secretions at bronchoscopy
PaO2, Arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; PEEP,
positive end-expiratory pressure.
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Xcause of death in the different donor PaO2 cohorts is not
consistent enough to draw conclusions between those do-
nors with a PaO2 of less than 300mmHg as a group (cohorts
<200 mmHg and 201-300 mmHg) and those with ideal do-
nor PaO2 (cohorts 301-400 mm Hg and>400 mm Hg). In-
terestingly, it does appear that both donor cohorts with
a PaO2 of less than 300 were more likely to have a pulmo-
nary infection and to have been given steroids than those do-
nors with a PaO2 of more than 300 mm Hg. The centers
accepting these less than ‘‘ideal’’ donor lungs may have be-
lieved that the infections were the cause of the decreased
PaO2 and that the infections could be treated effectively af-
ter transplant. Therefore, it may be that the increased use of
donor lungs with low PaO2s is secondary to centers becom-
ing more confident that they can successfully treat donor
lung infections after transplant.
The retrospective nature of the study, the lack of granu-
larity of the database, and the incomplete population of cer-
tain data fields were all limitations to the study. Another
important limitation is that the timing of when the donor
PaO2 value was recorded in the database is not known.922 The Journal of Thoracic and Cardiovascular SurgThe donor PaO2 data available only represent a moment
in time and do not show trends in PaO2 or a response to
a low PaO2. Therefore, the effect of measures taken to op-
timize a donor lung with a recorded PaO2 of less than 300
mm Hg would not be captured in the database.
The current study suggests that despite a low donor PaO2,
if the other donor characteristics indicate that the lungs are
acceptable then those lungs should be considered for trans-
plantation. This is in agreement with the work of Reyes and
associates,17 which analyzed variances from current donorery c April 2012
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Xguidelines and found them to be frequent and have minor to
no impact on outcomes. Ideally, the findings of these series
may give clinicians more confidence when deciding to ac-
cept donor lungs that are not ‘‘ideal.’’ Interestingly, as docu-
mented in this series, this decision to use donor lungs with
a PaO2 of less than 300 mm Hg is being made already in
nearly a fifth of all LTxs being performed in the United
States. The decision to use lungs with less than ideal char-
acteristics will only become easier in the next few years
as ex vivo lung perfusion will allow these ‘‘marginal’’ donor
lungs to be reassessed and optimized before implantation.
Donor PaO2 does not appear to affect pulmonary graft
survival. Therefore, this result appears to provide an oppor-
tunity to substantially increase the donor lung pool and be-
gin to rebalance the donor–recipient imbalance. We are not
suggesting that donor PaO2 is not important when assessing
potential lung donors, but its level of importance in regard
to other criteria appears less than previously believed.References
1. Gabbay E, Williams TJ, Griffiths AP, Macfarlane LM, Kotsimbos TC,
Esmore DS, et al. Maximizing the utilization of donor organs offered for lung
transplantation. Am J Respir Crit Care Med. 1999;160:265-71.
2. Straznicka M, Follette DM, Eisner MD, Roberts PF, Menza RL, Babcock WD.
Aggressive management of lung donors classified as unacceptable: excellent re-
cipient survival one year after transplantation. J Thorac Cardiovasc Surg. 2002;
124:250-8.
3. Pierre AF, Sekine Y, HutcheonMA,Waddell TK, Keshavjee SH. Marginal donor
lungs: a reassessment. J Thorac Cardiovasc Surg. 2002;123:421-8.
4. Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor
criteria may expand the donor pool without adverse consequence in lung trans-
plantation. J Heart Lung Transplant. 2000;19:1199-204.
5. Shumway SJ, Hertz MI, Petty MG, Bolman RM. Liberalization of donor criteria
in lung and heart-lung transplantation. Ann Thorac Surg. 1994;57:92-5.
6. McKellar SH, Durham LA, Scott JP, Cassivi SD. Successful lung transplant from
donor after cardiac death: a potential solution to shortage of thoracic organs.
Mayo Clin Proc. 2010;85:150-2.
7. Frost AE. Donor criteria and evaluation. Clin Chest Med. 1997;18:231-7.
8. Orens JB, Boehler A, Perrot M, Estenne M, Glanville AR, Keshavjee S, et al. A
review of lung transplant donor acceptability criteria. J Heart Lung Transplant.
2003;22:1183-200.
9. Harjula A, Baldwin JC, Starnes VA, Stinson EB, Oyer PE, Jamieson SW, et al.
Proper donor selection for heart-lung transplantation: the Stanford experience.
J Thorac Cardiovasc Surg. 1987;94:874-80.
10. US Department of Health and Human Services. Health Resources and Services
Administration OPTN Organ Procurement and Transplantation Network Web
site. http://optn.transplant.hrsa.gov/latestData/rptData.asp. Accessed April 2011.
11. Tuttle-Newhall JE, Krishnan SM, Levy MF, McBride V, Orlowski JP, Sung RS.
Organ donation and utilization in the United States: 1998-2007. Am J Transplant.
2009;9:879-93.
12. Mason DP, Murthy SC, Gonzalez-Stawinski GV, Budev MM, Mehta AC,
McNeill AM, et al. Early experience with lung transplantation using donors after
cardiac death. J Heart Lung Transplant. 2008;27:561-3.
13. Mason DP, Thuita L, Alster JM, Murphy SC, Budev MM, Mehta AC, et al.
Should lung transplantation be performed using donation after cardiac death?
The United States experience. J Thorac Cardiovasc Surg. 2008;136:1061-6.
14. Snell GI, Levvey BJ, Oto T, McEgan R, Pilcher D, Davies A, et al. Early lung
transplantation success utilizing controlled donation after cardiac death donors.
Am J Transplant. 2008;8:1282-9.
15. Cypel M, Yeung JC, Keshavjee S. Novel approaches to expanding the lung donor
pool: donation after cardiac death and ex-vivo conditioning. Clin Chest Med.
2011;32:233-44.
16. Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, et al. Normothermic
ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364:
1431-40.The Journal of Thoracic and Ca17. Reyes KG, Mason DP, Thuita L, Nowicki ER, Murthy SC, Pettersson GB, et al.
Guidelines for donor lung selection: time for revision? Ann Thorac Surg. 2010;
89:1756-65.
18. Sundaresan S, Semenkovich J, Ochoa L, Richardson G, Trulock EP, Cooper JD,
et al. Successful outcome of lung transplantation is not compromised by the use
of marginal lungs. J Thorac Cardivasc Surg. 1995;109:1075-9.
19. Lardinois D, Banysch M, Korom S, Hillinger S, Rousson V, Boehler A, et al. Ex-
tended donor lungs: eleven years experience in a consecutive series. Eur J Car-
diothorac Surg. 2005;27:762-7.
20. Puskas JD, Winton TL, Miller DJ, Scavuzzo M, Patterson GA. Unilateral donor
lung dysfunction does not preclude successful contralateral single lung transplan-
tation. J Thorac Cardiovasc Surg. 1992;103:1015-7.Discussion
Dr Thomas K. Waddell (Toronto, Ontario, Canada). Dr Mo-
rales, thank you for an interesting analysis and for sending the pa-
per in advance.
The subject of appropriate criteria for acceptance of the donor
lung has been extensively discussed, and there is a consensus
that many usable organs are ultimately rejected for poorly evalu-
ated criteria. You are to be congratulated for revisiting this issue.
Increasingly sophisticated analyses have been brought to bear,
and this is one of my major concerns regarding your paper. Two
approaches were taken in this analysis. One was to divide the co-
hort into 4 groups, and there was no difference in survival using
a log–rank analysis. In the second analysis you took all 21 donor
variables that were available and put them into a multivariable
analysis. Once again, donor PaO2 was not statistically significant.
Why did you not deal with the subject of recipient covariants?
You did show in the first analysis that there were no major differ-
ences. However, I would refer you to a very interesting analysis by
Reyes from the Cleveland Clinic published in The Annals of Tho-
racic Surgery in June of 2010 that took essentially the same data
set from UNOS and came to very different conclusions. In partic-
ular, Reyes’ group showed that a PaO2 of less than 230 mmHgwas
a problem. Even more emphatically, there was an analysis by Hen-
nessy from the University of Virginia group that took the UNOS
data from an even larger data set and found that there was in fact
an adverse effect of high PaO2. Thus we have 3 analyses from
the same data source that have come to 3 different conclusions.
In particular, yours is one that does not have any correction for re-
cipient characteristics, and I wonder if you could address why not.
DrMorales. The fact that 3 different conclusions have been de-
rived from the same database will demonstrate that it is probably
unclear whether donor PaO2 really does have an effect on graft sur-
vival. Three different institutions have looked at it and have not
come up with a consistent finding. We thought that we accounted
for recipient characteristics with the fact that when we analyzed
them in subgroups, they really did not differ clinically. These
things did not really differ by age or by weight, except for the
fact that more double LTxs were done with donors who had
a PaO2 that was lower. Thus I think that we did look at recipient
characteristics in our different subgroups.
Dr Waddell. Some of the recipient characteristics that you
looked at were not actually the ones that are most tightly linked
to outcome, and that would be a limitation.
My second question concerns what I consider to be one of the
more interesting findings, and you did not really remark on it.
The statistically significant donor variable that was associatedrdiovascular Surgery c Volume 143, Number 4 923
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Xwith poor outcome was in fact steroid use. You could make the
similar argument in your introduction that steroid use in the donor
was introduced with very little evidence base, and I found it inter-
esting that the use of steroids was associated with a hazard ratio of
1.7, meaning quite bad for long-term outcome. Do you want to
speculate on why that might be? Do you think we need to revisit
the use of steroids? Do you think we should do a randomized trial
to evaluate it?
Dr Morales. Thank you for your comments.
I did not put that in the presentation, but it is true that steroid use
did come out in the analysis. My transplant program thought long
and hard about why that would be, and we were not quite sure, es-
pecially since in the ex vivo protocols, we are now using steroids
during that time to help recover the lung.
Dr Bryan F. Meyers (St Louis, Mo). Right now I think LTx is
a luxurious therapy. With the amount of benefit it provides, it is
very expensive, both to do it and tomaintain the patients afterward.
Future analysis on something like this has to look at the efficiency
of the procedure as well as the early outcomes of survival or non-
survival. It we take perfect lungs and use them, we are going to get
a certain baseline outcome for a baseline expenditure. As we begin
using more risky lungs, we will encounter a more complex and
more expensive perioperative course. The likelihood of bypass
and extracorporeal membrane oxygenation will increase. The
risk of acute retransplantation will increase, and the longer-term
benefit will be diminished as well. I think that your first cut on
this is useful and thought-provoking. However, we need to get be-
yond just the most elemental evaluation of something like the do-
nor PaO2 and look at the incremental cost and the incremental
benefit that we would get by extending the use of donors that are
less than optimal.
DrMorales. Thank you for your comments. I agree. Things like
the UNOS database, the Nationwide Input Sample database, and
other administrative databases are problematic in that they only
supply short-term follow-up. We are starting, especially with
The Society of Thoracic Surgeons database, to think of linking
these to longer-term follow-ups, such as the Social Security Death
Master File or the National Death Index, from which long-term
mortality can be obtained. If something like the UNOS database
could be connected it to the Social Security Death Master File,
then the long-term effect of donor PaO2 on these grafts could be
determined. I think that should be a way to empower most of
our surgical databases, which are always limited by the fact that
we do not have long-term follow-up.
Dr Marcelo Cypel (Toronto, Ontario, Canada). I have 1 com-
ment and 2 quick questions.
One of the major problems with these data is that the PaO2 was
collected before you opened the chest and recruited the lungs. I
would imagine with the 20%, it would be a much smaller number
that would actually have a PaO2 less than 300 when you have op-
timized conditions.
My first question is this: what do you mean by graft survival
here, and why didn’t you use the ISHLT primary graft dysfunction
scores? I am not sure what graft survival means in days, as you
showed there.
The second question is whether you see a correlation of the im-
plementation of the lung allocation score with the increased num-
bers of lungs being assessed with PaO2s less than 300 mm Hg.924 The Journal of Thoracic and Cardiovascular SurgDr Morales. To answer your questions, we did not look at the
lung allocation score. By graft survival, we mean survival either
to retransplantation or to death. I do realize, and I mentioned this
as a limitation, that obviously you could have a PaO2 of 300 or
250, then take them to the operating room, recruit the lungs, and
thenfind that the PaO2 is 400.But I think it is surprising. Ifwe polled
everyone before we gave this presentation and asked what percent-
age of people in the UNOS database has a PaO2 less than 300, I’m
not sure many people would have said 20%. I think it just brings up
the fact that we have all grown up talking about PaO2s over 300, but
that level is not really established in any real data, and so I think it is
thought-provoking. Again, I also think when you get a donor call
and the first PaO2 is 200 mm Hg on 100% FiO2, unless your recip-
ient is very sick, many people would not think these lungs were ac-
ceptable. Perhaps this study will make people think a little bit more
about whether such lungs might be usable.
Dr Ankit Bharat (St Louis, Mo). Thank you for an interesting
presentation.
One of my concerns is that you demonstrated that there is no
difference in the long-term graft survival, and I presume this is
looking at chronic rejection. We know chronic rejection has a mul-
tifactorial pathology and is affected by multiple other variables. I
was wondering whether you looked at the short-term or the acute
events, such as development of primary graft dysfunction, sepsis,
and things like 30-day mortality in these patients and found any
effects in patients who had low PaO2s compared with those who
had lungs with a better PaO2. My second question is, if there
were such differences, is it possible that the differences in treat-
ment between these 2 groups of patients in the short term affected
their long-term survival and development of chronic rejection?
Dr Morales. The 2 things that we did look at were acute rejec-
tion in the hospital and length of stay, neither of which was statis-
tically different between the 2 groups. You are right. Perhaps if you
took a set of lungs with a PaO2 that was 250, you would take per-
haps better care of those lungs postoperatively. Obviously, I cannot
comment on that through a database.
Dr Joel D. Cooper (Philadelphia, Pa). I rise to discuss a point
in history. I enjoyed your paper very much.
The 300 mm Hg level is something that we inherited as well, in
the early days. I must say that I learned a great deal from the Stan-
ford group about heart–lung transplants. When we began getting
into heart–lung and lung transplants, we visited there and tried
to learn as much as we could from them. Perhaps that is where it
arose. I would also point out that in the early days, we and others
did everything possible to eliminate any adverse effects of donor
lung ischemia. We only used donors from our own city, we only
used very short ischemic times, and, yes, we only used donors in
whom the PaO2 was greater than 300 mm Hg, because at least
that is what I was advised. Obviously, as a procedure matures,
you are willing to take more risk, you do not believe that the whole
future of LTx rests in having every case successful, and you are
willing to use more marginal donors. I do not know where it arose,
and it was just an arbitrary standard, which seemed to be a very
high standard. We wanted to reduce as much as possible any ad-
verse factors that might affect the outcome in those early days.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). There is
a point, DrMorales, that still concerns me. There have been at least
2 previous major analyses of about 10,000 patients, plus or minusery c April 2012
Zafar et al Cardiothoracic Transplantation1000, looking at this fact. As you and Dr Waddell mentioned, they
came to different conclusions. That does not tell me that the PaO2
is not as important as we used to think. That may well be true, but it
speaks more to errors that we could make in throwing out a blanket
statement, like: ‘‘Don’t worry about PaO2 because it didn’t come
out as a significant factor.’’ I think it speaks also to the quality of
the data. What you have shown again is that lungs were used suc-
cessfully that at some point in the donor journey got a low PaO2
recorded by some coordinator in the middle of the night some-
where in the United States. That does not necessarily tell you
that PaO2 is not important. Again, it may not be as important,The Journal of Thoracic and Caand we are learning more about that and studying it, but I would
not think that that is a valid statement to make from the data that
you were working with.
DrMorales.Asmy conclusions stated, I am not actually stating
that donor PaO2 is not important, but how critical it is for predicting
graft survival especially at the level of 300 mm Hg is unclear.
Through the data that we analyzed, this is what we can conclude.
Again, I do not believe that we should not be concerned about
the donor PaO2, but its level of importance or the level of donor
PaO2 that is acceptable is something that we need to think about
and question.rdiovascular Surgery c Volume 143, Number 4 925
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